Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)

AstraZeneca303 enrolled

Overview

A Randomized, Open-Label, Multicenter, Comparator-Controlled Study to Examine the Effects of Exenatide Long-Acting Release (LAR) on Glucose Control (HbA1c) and Safety in Subjects with Type 2 Diabetes Mellitus Managed with Diet Modification and Exercise and/or Oral Antidiabetic Medications.

This trial is designed to examine the effect of exenatide once weekly compared to exenatide twice daily on glucose control and safety in subjects for at least 30 weeks. The study is also designed to examine glucose control during the transition from exenatide twice daily for 30 weeks to exenatide once weekly. Long-term safety and efficacy will be monitored during the open-ended assessment periods. This study will be conducted in approximately 300 subjects with type 2 diabetes treated with diet modification and exercise alone or in combination with a stable regimen of metformin, SU, thiazolidinedione (TZD), a combination of metformin and SU, a combination of metformin and TZD, or a combination of SU and TZD.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

303

Conditions

Type 2 Diabetes Mellitus

Interventions

exenatide, long acting releaseDRUG

exenatideDRUG

Eligibility

Sex: ALLMin age: 16 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Has type 2 diabetes mellitus treated with diet modification and exercise alone or in combination with a stable regimen of a combination of metformin, sulphonylureas, and thiazolidinediones for a minimum of 2 months at screening. * Hemoglobin A1c (HbA1c) of 7.1% to 11.0%, inclusive, at screening. * Body mass index (BMI) of 25 kg/m2 to 45 kg/m2, inclusive, at screening. * (For sub-study) Currently participating in open ended assessment period of main study 2993 LAR105 Exclusion Criteria: * Has been previously exposed to exenatide (Byetta®), exenatide LAR, or any glucagon-like peptide-1 (GLP-1) analog. * Received any investigational drug or has participated in any type of clinical trial within 30 days prior to screening. * Has been treated, is currently treated, or is expected to require or undergo treatment with any of the following excluded medications: * Alpha glucosidase inhibitor or meglitinide within 30 days of screening; * Insulin within 2 weeks prior to screening or insulin for longer than 1 week within 3 months of screening; * Regular use (\> 14 days) of drugs that directly affect gastrointestinal motility; * Regular use (\> 14 days) of systemic corticosteroids by oral, intravenous, or intramuscular route; or potent, inhaled, or intrapulmonary steroids known to have a high rate of systemic absorption; * Regular use (\> 14 days) of medications with addictive potential such as opiates and opioids; * Prescription or over-the-counter weight loss medications within 6 months of screening. * (For sub-study) Subjects will be terminated from study who do not participate in the dual chamber pen substudy

Locations (25)

Research Site 182

Encino, California, United States

Outcomes

Primary Outcomes

Change in HbA1c From Baseline to Week 30

Absolute change in HbA1c from Baseline (Day -3) to Week 30 \[Week 30 - Baseline\]

Time frame: Day -3, Week 30

Sub-study Relative Bioavailability of Exenatide When Administered Using the Exenatide Once Weekly Dual Chambered Pen and the Exenatide Once Weekly Single Dose Tray (Single Dose Tray-11 Weekly Doses Switch to Dual Chamber Pen-11 Weekly Dose)

Measure by Geometric mean ratio (GMR) of plasma exenatide average steady state concentration Css,avg at Visit 11-14 to Visit 24-27 with 90% confidence interval

Time frame: Week 22

Secondary Outcomes

Change in HbA1c From Baseline to Week 364

Absolute change in HbA1c from Baseline (Day -3) to Week 364

Time frame: Day -3, Week 364

Percentage of Subjects Achieving HbA1c Target of <7%

Percentage of subjects achieving HbA1c target value of \<7% at Week 30.

Time frame: Week 30

Percentage of Subjects Achieving HbA1c Target of <7%

Percentages of subjects achieving HbA1c target value of \<7% at Week 364

Time frame: Week 364

Percentage of Subjects Achieving HbA1c Target of <=6.5%

Percentages of subjects achieving HbA1c target values of \<=6.5% at Week 30.

Time frame: Week 30

Percentage of Subjects Achieving HbA1c Target of <=6.5%

Percentages of subjects achieving HbA1c target values of \<=6.5% at Week 364

Time frame: Week 364

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Research Site 171

La Jolla, California, United States

Research Site 518

San Diego, California, United States

Research Site 024

Walnut Creek, California, United States

Research Site

Colorado Springs, Colorado, United States

Research Site 057

Miami, Florida, United States

Research Site

Chicago, Illinois, United States

Research Site 149

Indianapolis, Indiana, United States

Research Site 099

Lexington, Kentucky, United States

Research Site 017

Detroit, Michigan, United States

...and 15 more locations

Percentage of Subjects Achieving HbA1c Target of <=6.0%

Percentage of subjects achieving HbA1c target values of \<=6.0% at Week 30.

Time frame: Week 30

Exenatide LAR Steady State Concentration From Week 29 to Week 30

Steady-state plasma exenatide concentration over the dosing interval of Week 29 to Week 30 (0-168 hours) was evaluated. Geometric mean for the average steady-state concentration and its 10th and 90th percentiles were reported.

Time frame: Week 29 to Week 30

Change in 2 Hours (2h) Postprandial Glucose From Baseline to Week 14

Change in 2h Postprandial Glucose from baseline (Day -3) to Week 14

Time frame: Day -3, Week 14

Sub-study Safety and Tolerability of Exenatide When Administered Using the Once Weekly Single Dose Tray and the Once Weekly Dual (Single Dose Tray-11 Weekly Doses Switch to Dual Chamber Pen-11 Weekly Dose)

Measure by geometric mean ratio of the maximum steady state plasma exenatide concentration Css, max at Visit 11-14 to Visit 24-27 with 90% confidence interval and incidence of treatment-emergent injection site adverse events.

Time frame: Week 22

Change in Body Weight From Baseline to Week 30

Change in body weight from baseline (Day -3) to Week 30

Time frame: Day -3, Week 30

Change in Body Weight From Baseline to Week 364

Change in body weight from baseline (Day -3) to Week 364

Time frame: Day -3, Week 364

Change in Fasting Plasma Glucose From Baseline to Week 30

Change in fasting plasma glucose from baseline (Day -3) to Week 30.

Time frame: Day -3, Week 30

Change in Fasting Plasma Glucose From Baseline to Week 364

Change in fasting plasma glucose from baseline (Day -3) to Week 364.

Time frame: Day -3, Week 364

Change in Blood Pressure From Baseline to Week 30

Change in Sitting Diastolic Blood Pressure and Sitting Systolic Blood Pressure from baseline to Week 30

Time frame: Day -3, Week 30

Change in Blood Pressure From Baseline to Week 364

Change in Sitting Diastolic Blood Pressure and Sitting Systolic Blood Pressure from baseline to Week 364

Time frame: Day -3, Week 364

Change in Total Cholesterol From Baseline to Week 30

Change in total cholesterol from baseline (Day -3) to Week 30.

Time frame: Day -3, Week 30

Change in Total Cholesterol From Baseline to Week 364

Change in total cholesterol from baseline (Day -3) to Week 364.

Time frame: Day -3, Week 364

Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 30

Change in high-density lipoprotein cholesterol (HDL-C) from baseline (Day -3) to Week 30.

Time frame: Day -3, Week 30

Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 364

Change in high-density lipoprotein cholesterol (HDL-C) from baseline (Day -3) to Week 364.

Time frame: Day -3, Week 364

Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 364

Change in low-density lipoprotein cholesterol (LDL-C) from baseline (Day -3) to Week 364.

Time frame: Day -3, Week 364

Ratio of Triglycerides at Week 30 to Baseline

Ratio of triglycerides (measured in mg/dL) at Week 30 to baseline (Day -3). Log (Postbaseline Triglycerides) - log (Baseline Triglycerides); change from baseline to endpoint is presented as ratio of endpoint to baseline.

Time frame: Day -3, Week 30

Ratio of Triglycerides at Week 364 to Baseline

Ratio of triglycerides (measured in mg/dL) at Week 364 to baseline (Day -3). Log (Postbaseline Triglycerides) - log (Baseline Triglycerides); change from baseline to endpoint is presented as ratio of endpoint to baseline.

Time frame: Day -3, Week 364

Assessment on Event Rate of Treatment-emergent Hypoglycemic Events With SU Use at Screening

The major hypoglycemia category included events that, in the judgment of the investigator or physician, resulted in loss of consciousness, seizure, coma, or other change in mental status consistent with neuroglycopenia, in which symptoms resolved after administration of intramuscular glucagon or intravenous glucose, required third-party assistance, and was accompanied by a blood glucose concentration of less than 54 mg/dL prior to treatment, whether or not symptoms of hypoglycemia were perceived by the subject. The minor hypoglycemia were accompanied by a blood glucose concentration of less than 54 mg/dL prior to treatment and not classified as major hypoglycemia.

Time frame: Day 1 to Week 364

Assessment on Event Rate of Treatment-emergent Hypoglycemic Events With Non-SU Use at Screening

Time frame: Day 1 to Week 364